382 related articles for article (PubMed ID: 27345413)
1. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
2. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
[TBL] [Abstract][Full Text] [Related]
3. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
6. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
8. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
9. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
11. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
12. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
13. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
14. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
15. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
16. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
17. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
18. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
19. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
